Click on headlines below to download research

Capital markets day take aways
NeuroVive Pharmaceutical | 23/10/2019

On 9 October 2019, NeuroVive held its capital markets day. Management presented its strategic focus on the company's primary mitochondrial disease…

Steady progress with core assets
NeuroVive Pharmaceutical | 12/09/2019

NeuroVive’s core R&D assets in genetic mitochondrial diseases have made steady progress over the past several months. Notable newsflow includes…

Several R&D events within cash reach
NeuroVive Pharmaceutical | 12/06/2019

The combined net proceeds of SEK108m from a rights issue and direct placement completed in Q119 ensure NeuroVive Pharmaceutical’s operations will…

New funds allow progress of key trials
NeuroVive Pharmaceutical | 04/04/2019

In February 2019, NeuroVive completed a rights issue, which was followed by a private placement. These brought in a total of SEK108.1m (net estimated),…

SEK124m rights issue underway 80% guaranteed
NeuroVive Pharmaceutical | 17/12/2018

On 10 December 2018, NeuroVive announced a rights issue (subject to EGM approval) aiming to raise up to SEK123.8m gross at a price of SEK1.35 per share,…

Licensing deal and R&D pipeline progress
NeuroVive Pharmaceutical | 05/10/2018

On 18 June 2018, NeuroVive announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a private…

KL1333 Ph I positive; rights issue oversubscribed
NeuroVive Pharmaceutical | 04/06/2018

On 27 April 2018, NeuroVive announced that the planned rights issue was oversubscribed (104%), delivering SEK78.5m in gross proceeds and funding the operations…

Bitesize briefing - NeuroVive Pharmaceutical
Bitesize briefing - NeuroVive Pharmaceutical | 24/04/2018

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of…

Rights issue to reach several R&D events
NeuroVive Pharmaceutical | 05/03/2018

NeuroVive’s planned rights issue (subject to approval at the EGM) is expected to bring in a minimum guaranteed amount of at least SEK55m (gross),…

Two new trials and likely out-licensing in 2018
NeuroVive Pharmaceutical | 14/12/2017

NeuroVive has made progress on multiple fronts over the past few months with both its core asset portfolio and non-core projects for out-licensing. Notable…